Remove Biomarkers Remove Cardiovascular Disease Remove Plaque
article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

This clearance comes in advance of disease-modifying therapies on the horizon expected to help clinicians use this biomarker to guide patients to improved cardiovascular health, saidBrad Moore, president and CEO at Roche Diagnostics North America. The development of the Tina-quant Lipoprotein (a) Gen.2 J Clin Lipidol.

article thumbnail

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

Frontiers in Cardiovascular Medicine

Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors.

Plaque 59
article thumbnail

Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

DAIC

I am excited about the potential of the FAI-Score biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation." Details of the study, included in a written statement issued by Caristo Diagnostics, follow.

article thumbnail

Abstract 4146638: Comparative Assessment of hsCRP and Apolipoprotein B as ASCVD Risk Biomarkers

Circulation

Introduction/Background:According to the American Heart Association, the accumulation of plaque in the walls of arteries is identified as the primary cause of atherosclerotic cardiovascular disease (ASCVD). While hsCRP shows moderate diagnostic accuracy, it is not sufficient as a standalone ASCVD risk diagnostic marker.

article thumbnail

Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G?Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease

Journal of the American Heart Association

BackgroundPatients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.

Aortic 40
article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 7 Research has shown inflammation plays a significant role in the development of atherosclerosis and ASCVD,8-10 and even the formation of plaque.11 4 In the U.S.

article thumbnail

Physiology Friday #218: The Longevity Advantage of Elite Middle Distance Runners

Physiologically Speaking

Most of the evidence on the harms of extreme exercise is related to a biomarker of cardiovascular disease known as coronary artery calcification or CAC. ” Biomarkers of cardiovascular disease are one thing. ” Biomarkers of cardiovascular disease are one thing. population.